• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2024 Fiscal Year Final Research Report

Establishment of a Sleep Cycle-Oriented Intranasal Brain Drug Delivery System and Its Application to the Treatment of Neurodegenerative Disorders

Research Project

  • PDF
Project/Area Number 22K06709
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 47060:Clinical pharmacy-related
Research InstitutionUniversity of Toyama

Principal Investigator

Inoue Daisuke  富山大学, 学術研究部薬学・和漢系, 助教 (50550620)

Project Period (FY) 2022-04-01 – 2025-03-31
Keywords経鼻投与 / 脳内薬物送達 / 中枢神経系疾患 / 製剤開発
Outline of Final Research Achievements

In this study, we aimed to develop an efficient drug delivery system to the brain via intranasal administration that could contribute to the treatment of neurodegenerative diseases. Specifically, it adopted a strategic, dual approach: (1) designing a highly efficient brain delivery method that takes into account physiological functions in vivo, and (2) optimizing intranasal formulations. It is currently investigating whether nasal-to-brain drug delivery can be controlled from a physiological perspective by elucidating the influence of a sleep/wake cycle on the brain distribution of drugs after intranasal administration. In parallel, it was successfully developed an optimized intranasal formulation capable of achieving more efficient nose-to-brain drug delivery. This formulation demonstrated the suppression of chronic neuroinflammation, which is associated with the onset of neurodegenerative diseases.

Free Research Field

薬物送達学、製剤学、薬物動態学

Academic Significance and Societal Importance of the Research Achievements

本研究は、超高齢化が進み世界的に急増している一方、根治的治療法の開発が遅れている神経変性疾患に対する新規薬物療法を提供することを目指した基礎的研究である。本研究は、神経変性疾患に対する治療薬開発でいまだ困難な課題である脳への薬物送達性を高める基盤技術の開発を目的としている。本技術が確立できれば中枢創薬の飛躍的発展に繋がる基礎的知見を提供できると思われ、その学術的意義は大きい。また得られた研究成果をさらに発展させることで、神経変性疾患に対する新たな薬物治療アプローチが創出できれば、社会的意義は大きいものと考えられる。

URL: 

Published: 2026-01-16  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi